Surrozen, Inc. (SRZN)
NASDAQ: SRZN · Real-Time Price · USD
11.20
-0.35 (-3.03%)
Feb 21, 2025, 4:00 PM EST - Market closed
Surrozen Revenue
Surrozen had revenue of $10.00M in the quarter ending September 30, 2024. This brings the company's revenue in the last twelve months to $10.00M, down -20.00% year-over-year.
Revenue (ttm)
$10.00M
Revenue Growth
-20.00%
P/S Ratio
2.94
Revenue / Employee
$238,095
Employees
42
Market Cap
36.40M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 12.50M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
SRZN News
- 3 months ago - Surrozen to Present at Upcoming Healthcare Investor Conferences - GlobeNewsWire
- 3 months ago - Surrozen Provides Third Quarter 2024 Financial Results and Business Update - GlobeNewsWire
- 3 months ago - Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis - GlobeNewsWire
- 5 months ago - Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration - GlobeNewsWire
- 6 months ago - Surrozen Provides Second Quarter 2024 Financial Results and Business Update - GlobeNewsWire
- 9 months ago - Surrozen Publishes Study in ‘eLife' Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling - GlobeNewsWire
- 9 months ago - Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan - GlobeNewsWire
- 9 months ago - Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis - GlobeNewsWire